Related Experiment Videos
Growth hormone therapy in hypophosphatemic rickets
D M Wilson1, P D Lee, A H Morris
1Department of Pediatrics, Stanford University, Calif.
American Journal of Diseases of Children (1960)
|October 1, 1991
Summary
Growth hormone therapy improved bone metabolism in children with familial hypophosphatemic rickets. Treatment increased serum phosphate and growth rates, suggesting its potential benefit for this condition.
Area of Science:
- Pediatric Endocrinology
- Metabolic Bone Disease
Background:
- Familial hypophosphatemic rickets (FHR) is a rare genetic disorder affecting bone metabolism.
- Conventional therapy for FHR includes calcitriol and phosphate supplementation.
Purpose of the Study:
- To investigate the effects of growth hormone (GH) therapy on biochemical markers of bone metabolism in children with FHR.
- To assess the impact of GH on serum phosphate, calcitriol, osteocalcin, parathyroid hormone, and growth rate.
Main Methods:
- Eleven children with FHR received conventional therapy, followed by periods of no therapy, GH therapy alone, and combined therapy.
- Biochemical markers and growth rates were measured at baseline and during treatment phases.
- Nine subjects continued combined therapy for 24 weeks.
Main Results:
- GH therapy alone increased serum phosphate levels compared to no therapy.
- Calcitriol, osteocalcin, and parathyroid hormone levels increased with GH administration.
- Insulin-like growth factor I (IGF-I) z scores significantly increased during GH therapy.
- Combined therapy for 6 months led to increased growth rate z scores in nine subjects.
Conclusions:
- Exogenous growth hormone therapy demonstrates potential benefits in managing biochemical abnormalities and improving growth in children with familial hypophosphatemic rickets.
- GH may be a valuable adjunct to conventional therapy for FHR.